Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

Abstract Efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-4 inhibitor, were assessed in Japanese patients with type 2 diabetes. In a multicenter, double-blind, randomized, placebo-controlled trial in Japan, 151 patients with inadequate glycemic control [HbA 1c ≥6.5% to 1c was −0.65% (95% CI: −0.80, −0.50) with sitagliptin versus 0.41% (0.26, 0.56) with placebo [between-group difference = −1.05% (−1.27, −0.84); p p 1c p p